Related Experiment Video
Updated: May 30, 2026
Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
Abnormal peripheral chemokine profile in Huntington's disease.
Edward Wild1, Anna Magnusson, Nayana Lahiri
1UCL Institute of Neurology, London, UK; Bristol University, UK; Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; Lund University Diabetes Center Malmö Sweden and Department of Neurology, University of Ulm, Ulm, Germany.
Immune system activation in Huntington's disease (HD) involves specific chemokine changes. Elevated chemokine levels in plasma correlate with disease progression and clinical symptoms, offering potential biomarkers for HD.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Biomarker Discovery
Background:
- Huntington's disease (HD) is an inherited neurodegenerative disorder with known immune activation in the brain.
- Previous research established a progressive innate immune response in HD plasma.
- This study investigates specific immune molecules, chemokines, in HD pathogenesis.
Purpose of the Study:
- To quantify plasma chemokine levels in Huntington's disease patients across different disease stages.
- To identify specific chemokines that change with HD progression.
- To explore the correlation between chemokine levels and clinical disease severity.
Main Methods:
- Utilized multiplex ELISA to measure chemokine concentrations in plasma samples from HD subjects and controls.
- Analyzed chemokine profiles in relation to disease stage and clinical scores.
- Validated findings in an independent cohort of HD patients.
Main Results:
- Identified an altered plasma chemokine profile in Huntington's disease that progresses with the disease.
- Observed significant elevations in five chemokines (eotaxin-3, MIP-1β, eotaxin, MCP-1, MCP-4).
- Demonstrated linear increases in three chemokines (eotaxin-3, MIP-1β, eotaxin) with advancing disease stages.
- Found correlations between specific chemokine levels (MCP-1, eotaxin) and clinical assessments.
Conclusions:
- Chemokines, similar to cytokines, are implicated in the pathogenesis of Huntington's disease.
- Plasma chemokine profiles may serve as valuable indicators for tracking HD progression.
- Immune molecules like chemokines offer potential targets for understanding and managing HD.
